Novel noninvasive molecular imaging for monitoring rheumatoid arthritis

(Society of Nuclear Medicine and Molecular Imaging) A first-in-human Phase 1/Phase II study demonstrates that intravenous administration of the radiopharmaceutical imaging agent technetium-99m (99mTc) tilmanocept promises to be a safe, well-tolerated, noninvasive means of monitoring rheumatoid arthritis disease activity. At present, there is no reliable noninvasive way to directly monitor inflammation in joints of RA patients